Article Text

The effect of preinjury warfarin use on mortality rates in trauma patients: a European multicentre study
  1. Fiona E Lecky1,
  2. Mahad Omar2,
  3. Omar Bouamra1,
  4. Tom Jenks1,
  5. Antoinette Edwards1,
  6. Ceri E Battle3,
  7. Phillip A Evans1
  1. 1The Trauma Audit and Research Network, University of Manchester, Salford, UK
  2. 2NISCHR Haemostasis Biomedical Research Unit, Morriston Hospital, Swansea, Wales
  3. 3NISCHR Haemostasis Biomedical Research Unit, Epidemiology Division, Morriston Hospital, Swansea, Wales
  1. Correspondence to Dr Ceri Battle, Physiotherapy Department, Morriston Hospital Morriston, Swansea, SA6 6NL, UK; Ceri.battle{at}


Objective To define the relationship between preinjury warfarin use and mortality in a large European sample of trauma patients.

Methods A multicentred study was conducted using data collated from European (predominately English and Welsh) trauma receiving hospitals. Patient data from the Trauma Audit and Research Network database from 2009 to 2013 were analysed. Univariate and multivariate logistic regression was used to estimate OR for mortality associated with preinjury warfarin use in the whole adult trauma cohort and a matched sample of patients comparable in terms of age, gender, GCS, pre-existing medical conditions and injury severity.

Results A total of 136 617 adult trauma patients (2009–2013) were included, with 499 patients reported to be using warfarin therapy at the time of trauma. Preinjury warfarin use was associated with a significantly higher mortality rate at 30 days postinjury compared with the non-users. Following adjustment of age, injury severity and GCS, preinjury warfarin use was associated with increased mortality in trauma patients (adjusted OR 2.14; 95% CI 1.66 to 2.76; p<0.001). In the matched subset, 22% of warfarinised trauma patients died compared with 16.3% of non-warfarinised trauma patients with comparable age, injury severity and GCS (adjusted OR 1.94; 95% CI 1.25 to 3.01; p=0.003).

Conclusions Preinjury warfarin use has been demonstrated to be an independent predictor of mortality in trauma patients. Clinicians managing major trauma patients on warfarin need to be aware of the vulnerability of this group.

  • Trauma
  • Trauma, epidemiology
  • haematology

Statistics from

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.